BENGALURU: According to an announcement issued on October 2 by the business Merck, and Ridgeback Biotherapeutic, the investigational Covid-19 medication Molnupiravir could be promising in treating mild to moderate corona patients.
Doctors believe this could be effective in treating Covid patients early on, based on current data, as the company reported a 50% reduction in hospitalisation and death.
“While we have treatments for intermediate to severe patients, mild ones are still a challenge. This medication has the potential to change everything.” Dr. Chinnadurai R, lead consultant, Department of Critical Care, Aster RV Hospital, said, “It can be administered orally in the out-patient department.”
By day 29, 7.3 percent of individuals who received the medicine were either hospitalised or had died, compared to 14.1 percent of placebo patients, according to the data collected from 775 patients.
Even though Molnupiravir induces lethal mutagenesis, which lowers viral reproduction, the study has yet to be peer-reviewed and published. Dr. Anoop Amarnath, head of the Scientific Board and chairman of Geriatric Medicine at Manipal Hospitals, said, “We have to see the clinical benefit on the ground and also await regulatory approval.”
Cipla, Dr. Reddy’s, Emcure, Sun Pharma, and Torrent are among the five Indian businesses conducting studies for this medicine.